Deletion of the tissue response against alginate-pll capsules by temporary release of co-encapsulated steroids

Bünger, Carsten Michael; Tiefenbach, B; Jahnke, Annika; Gerlach, Christian; Freier, Th.; Schmitz, K.-P.; Hopt, Ulrich T.; Schareck, W.; Klar, E.; Vos, Paul de

doi:10.1016/j.biomaterials.2004.07.017

Cited by 80 publications

(52 citation statements)

References 35 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An inflammatory response cannot be avoided since it starts already with the mandatory surgery to implant the capsules and since it cannot be avoided that some capsules contain imperfection [21,35,42,56] and provoke a response. Therefore, the current strategy of many research groups is to apply anti-inflammatory drugs to inhibit the activation of monocytes and macrophages in the vicinity of the capsules [44,45]. In most cases these drugs are applied in the immediate posttransplant period up to two weeks.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The association between in vivo physicochemical changes and inflammatory responses against alginate based microcapsules

et al. 2012

View full text Add to dashboard Cite

Citation for published version (APA): de Vos, P., Spasojevic, M., de Haan, B., & Faas, M. M. (2012). The association between in vivo physicochemical changes and inflammatory responses against alginate based microcapsules. Biomaterials, 33(22), 5552-5559. a b s t r a c t Application of alginate-polylysine (PLL) capsules for immunoisolation of living cells are suffering from a varying degree of success and large lab-to-lab variations. In this study we show that these differences in success rates can be attributed to alginate dependent essential physicochemical changes of the properties of capsules in vivo that will render the capsules more susceptible to inflammatory responses. Capsule properties were studied before and after implantation by XPS, by immunocytochemistry, and by measuring zeta potentials. We studied a capsule type which provokes for unknown reasons a strong inflammatory response, i.e. high-guluronic (G) alginate capsules and a capsule type with near identical physicochemical properties but which evokes a minimal inflammatory response, i.e. intermediate-G alginate capsules. The cause of the difference in response was a decrease in nitrogen content on high-G capsules due to detachment of PLL in vivo and an increase of the zeta-potential. Our data illustrate an important overlooked phenomena; the physicochemical properties are not necessarily the properties after exposure to the in vivo microenvironment and might induce undesired inflammatory responses and failure of encapsulated cellular grafts.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It has been assumed that the reaction against capsules is complete within seven days after implantation [35,44,45]. This assumption is based on quantification of the number of capsules that is affected by cellular overgrowth and not on analyses of the composition of the overgrowth.…”

Section: Tissue Response At Week 2 4 and 8 Weeks After Implantationmentioning

confidence: 99%

The association between in vivo physicochemical changes and inflammatory responses against alginate based microcapsules

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Encapsulation of islets along with dexamethasone, a corticosteroid serving as local immune suppression, can improve islet survival in mice recipients compared to those islets alone [53]. In another study, co-encapsulation of mouse monocyte macrophage cells and hamster kidney cells with ibuprofen improved the encapsulated cell survival both in vitro and in vivo [54].…”

Section: Co-encapsulationmentioning

confidence: 99%

Avoiding Immunosuppression for Islet Transplantation: Use of Protective Biomaterials

Alexander¹,

Nguyen²,

Flores³

et al. 2017

Challenges in Pancreatic Pathology

View full text Add to dashboard Cite

Islet transplantation, with the advent of the Edmonton protocol in 2000, has offered a significant alternative for long-lasting treatment of type 1 diabetes. However, the immunosuppression required for transplantation has the cytotoxic effect on pancreatic islets, and thus limiting the long-term efficacy of the transplant. Immediate loss of islets after transplant was also observed because of immediate blood-mediated inflammatory response (IBMIR), which kills islets transplanted in the liver through portal vein. There is also commonly a lack of microvascular blood supply to the transplanted islets. In this chapter, we will review the variety of technologies used to protect transplanted islets against toxicity of immunosuppression, immune rejection, and inflammatory response. We will evaluate the mechanisms of these technologies and their progress in solving the challenges to islet transplantation. The technologies include encapsulation of transplanted islets in various polymers, transplants in sites other than the liver, and creation of new prevascularized transplant site. These technologies offer several mechanisms to prevent immune rejection or immediate contact with cytotoxic inflammatory response, in addition to maintaining islet integrity. New transplant sites are also being developed to support the islets, by allowing establishment of microvasculature and innervation, prior to addition of the islets.

show abstract

“…Although alginate remains the most popular hydrogel of choice, agarose [115,116], chitosan [117], methacrylic acid [118], methyl methacrylate [119], polyamide [120,121], PVA [122], PEG [123,124], 2-hydroxyethyl methacrylate (HEMA) [125,126], AN69 (a copolymer of acrylonitrile and sodium-methallyl sulfonate) [127], and collagens type I and IV [128] are all being evaluated for use in islet and stem cell encapsulation. Stimuli-responsive synthetic hydrogels are commonly employed in cell encapsulation and tissue engineering.…”

Section: Synthetic Scaffoldsmentioning

confidence: 99%

Encapsulation technologies in beta cell replacement therapies for Type 1 diabetes

Krishnan¹,

Imagawa²,

Foster³

et al. 2016

Nanomaterials and Regenerative Medicine

View full text Add to dashboard Cite

Deletion of the tissue response against alginate-pll capsules by temporary release of co-encapsulated steroids

Cited by 80 publications

References 35 publications

The association between in vivo physicochemical changes and inflammatory responses against alginate based microcapsules

The association between in vivo physicochemical changes and inflammatory responses against alginate based microcapsules

Avoiding Immunosuppression for Islet Transplantation: Use of Protective Biomaterials

Encapsulation technologies in beta cell replacement therapies for Type 1 diabetes

Contact Info

Product

Resources

About